Health economic evaluations of antidepressants: A review

✍ Scribed by Timothy R. Hylan; Don P. Buesching; Gary D. Tollefson

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 91 KB
• Volume: 7
• Category: Article
• ISSN: 1091-4269
• DOI: 10.1002/(sici)1520-6394(1998)7:2<53::aid-da1>3.0.co;2-6

✦ Synopsis

In an era of constrained health care financing, clinicians are increasingly faced with considering the economic consequences in addition to the clinical outcomes associated with initiating a patient on antidepressant therapy. This has increased the demand for health economic studies comparing antidepressant use and associated health care expenditures in clinical practice. These health economics studies have used methods ranging from clinical trials to other types of analyses including prospective naturalistic trials or retrospective studies which may be less familiar to clinicians. Prospective and retrospective health economics studies performed in clinical practice complement the experience gained from clinical trials in assessing antidepressant use and economic outcomes in light of patient and provider behavior within the usual care environment of a complex health care system. Broadly considered, health economic studies of antidepressants have consistently found differences in clinical practice between the tricyclic antidepressants (TCAs) and the selective serotonin reuptake inhibitors (SSRIs) as well as among the SSRIs. These differences relate to the pattern and duration of antidepressant use as well as total direct health care expenditures. Future health economic research studies in clinical practice should focus on the economic consequences of long-term antidepressant use as well as the impact of antidepressant use on indirect costs such as productivity and absenteeism. Depression and Anxiety 7:

53-64, 1998.